SUNRISE, Fla., Dec. 16, 2008 — (HSMN NewsFeed) — Bioheart, Inc. (NasdaqCM:BHRT ) announced today that it’s planning to spin out or sell off its interest in several non-core technology platforms in order to intensify its strategic focus on the treatment …
Devices, Regenerative Medicine, Cardiology
Bioheart, MyoStim, MyoValve, Biopace, AortaCell

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Bioheart, Inc. Announces Plans to Divest Non-Core Products to Increase Focus On Heart Failure Treatments”
Leave a Comment